Drug Type Synthetic peptide |
Synonyms NNC-26-0161 |
Target |
Mechanism GHRH agonists(Growth hormone releasing factor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC38H49N9O5 |
InChIKeyNEHWBYHLYZGBNO-BVEPWEIPSA-N |
CAS Registry170851-70-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ipamorelin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrointestinal dysfunction | Phase 2 | US | 01 Apr 2011 | |
Ileus | Phase 2 | US | 01 Apr 2008 |
Phase 2 | 117 | fzvwgepzij(esowbqmaln) = Overall incidence of any treatment-emergent adverse events was 87.5% in the ipamorelin group and 94.8% in placebo group qqdlthdltu (yzogwurqft ) | Negative | 01 Dec 2014 | |||
Placebo |